Immunomodulation by LongoVital in patients with recurrent aphthous ulceration

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Immunomodulation by LongoVital in patients with recurrent aphthous ulceration. / Pedersen, A; Klausen, B; Hougen, H P; Ryder, L; Winther, K.

In: Journal of Oral Pathology & Medicine, Vol. 19, No. 8, 1990, p. 376-80.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pedersen, A, Klausen, B, Hougen, HP, Ryder, L & Winther, K 1990, 'Immunomodulation by LongoVital in patients with recurrent aphthous ulceration', Journal of Oral Pathology & Medicine, vol. 19, no. 8, pp. 376-80.

APA

Pedersen, A., Klausen, B., Hougen, H. P., Ryder, L., & Winther, K. (1990). Immunomodulation by LongoVital in patients with recurrent aphthous ulceration. Journal of Oral Pathology & Medicine, 19(8), 376-80.

Vancouver

Pedersen A, Klausen B, Hougen HP, Ryder L, Winther K. Immunomodulation by LongoVital in patients with recurrent aphthous ulceration. Journal of Oral Pathology & Medicine. 1990;19(8):376-80.

Author

Pedersen, A ; Klausen, B ; Hougen, H P ; Ryder, L ; Winther, K. / Immunomodulation by LongoVital in patients with recurrent aphthous ulceration. In: Journal of Oral Pathology & Medicine. 1990 ; Vol. 19, No. 8. pp. 376-80.

Bibtex

@article{1a5f326963d74a3b87c0aefc40620dce,
title = "Immunomodulation by LongoVital in patients with recurrent aphthous ulceration",
abstract = "LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. Peripheral lymphocyte subsets: T-helper/CD4 (OKT4+) and T-suppressor/cytotoxic/CD8 (OKT8+) were studied quantitatively in 31 otherwise healthy patients with minor recurrent aphthous ulceration (RAU) during 6 months' daily LV intake in a double-blind, randomized, crossover 1-year study. Fourteen had had LV during the first 6 months (GrA) and 17 LV during the latter 6 months (GrB). OKT4+ percentages increased significantly during the LV period in both groups (P less than 0.05). OKT8+ percentages increased in both groups, however, only significantly in GrA (P less than 0.05). It is concluded that LV acts as an immunostimulator in patients with RAU and that the increase in T-lymphocyte subsets may account for the previously reported benefit of LV in RAU prevention.",
keywords = "Adult, Aged, Analysis of Variance, CD4-Positive T-Lymphocytes, Double-Blind Method, Female, Humans, Killer Cells, Natural, Lymphocyte Activation, Male, Middle Aged, Phytotherapy, Recurrence, Stomatitis, Aphthous, T-Lymphocytes, Helper-Inducer, T-Lymphocytes, Regulatory, Ulcer",
author = "A Pedersen and B Klausen and Hougen, {H P} and L Ryder and K Winther",
year = "1990",
language = "English",
volume = "19",
pages = "376--80",
journal = "Journal of Oral Pathology and Medicine",
issn = "0904-2512",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Immunomodulation by LongoVital in patients with recurrent aphthous ulceration

AU - Pedersen, A

AU - Klausen, B

AU - Hougen, H P

AU - Ryder, L

AU - Winther, K

PY - 1990

Y1 - 1990

N2 - LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. Peripheral lymphocyte subsets: T-helper/CD4 (OKT4+) and T-suppressor/cytotoxic/CD8 (OKT8+) were studied quantitatively in 31 otherwise healthy patients with minor recurrent aphthous ulceration (RAU) during 6 months' daily LV intake in a double-blind, randomized, crossover 1-year study. Fourteen had had LV during the first 6 months (GrA) and 17 LV during the latter 6 months (GrB). OKT4+ percentages increased significantly during the LV period in both groups (P less than 0.05). OKT8+ percentages increased in both groups, however, only significantly in GrA (P less than 0.05). It is concluded that LV acts as an immunostimulator in patients with RAU and that the increase in T-lymphocyte subsets may account for the previously reported benefit of LV in RAU prevention.

AB - LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. Peripheral lymphocyte subsets: T-helper/CD4 (OKT4+) and T-suppressor/cytotoxic/CD8 (OKT8+) were studied quantitatively in 31 otherwise healthy patients with minor recurrent aphthous ulceration (RAU) during 6 months' daily LV intake in a double-blind, randomized, crossover 1-year study. Fourteen had had LV during the first 6 months (GrA) and 17 LV during the latter 6 months (GrB). OKT4+ percentages increased significantly during the LV period in both groups (P less than 0.05). OKT8+ percentages increased in both groups, however, only significantly in GrA (P less than 0.05). It is concluded that LV acts as an immunostimulator in patients with RAU and that the increase in T-lymphocyte subsets may account for the previously reported benefit of LV in RAU prevention.

KW - Adult

KW - Aged

KW - Analysis of Variance

KW - CD4-Positive T-Lymphocytes

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Killer Cells, Natural

KW - Lymphocyte Activation

KW - Male

KW - Middle Aged

KW - Phytotherapy

KW - Recurrence

KW - Stomatitis, Aphthous

KW - T-Lymphocytes, Helper-Inducer

KW - T-Lymphocytes, Regulatory

KW - Ulcer

M3 - Journal article

C2 - 1979083

VL - 19

SP - 376

EP - 380

JO - Journal of Oral Pathology and Medicine

JF - Journal of Oral Pathology and Medicine

SN - 0904-2512

IS - 8

ER -

ID: 44354788